Stabilizing short-lived Schiff base derivatives of 5-aminouracils that activate mucosal-associated invariant T cells by Mak, Jeffrey Y. W. et al.
ARTICLE
Received 15 May 2016 | Accepted 16 Jan 2017 | Published 8 March 2017
Stabilizing short-lived Schiff base derivatives
of 5-aminouracils that activate mucosal-associated
invariant T cells
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Huimeng Wang3, Zhenjun Chen3, Jamie Rossjohn4,5,6, James McCluskey3, Ligong Liu1,2 & David P. Fairlie1,2
Mucosal-associated invariant T (MAIT) cells are activated by unstable antigens formed by
reactions of 5-amino-6-D-ribitylaminouracil (a vitamin B2 biosynthetic intermediate) with
glycolysis metabolites such as methylglyoxal. Here we show superior preparations of antigens
in dimethylsulfoxide, avoiding their rapid decomposition in water (t1/2 1.5 h, 37 C). Antigen
solution structures, MAITcell activation potencies (EC50 3–500 pM), and chemical stabilities
are described. Computer analyses of antigen structures reveal stereochemical and energetic
inﬂuences on MAIT cell activation, enabling design of a water stable synthetic antigen
(EC50 2 nM). Like native antigens, this antigen preparation induces MR1 refolding and
upregulates surface expression of human MR1, forms MR1 tetramers that detect MAITcells in
human PBMCs, and stimulates cytokine expression (IFNg, TNF) by human MAIT cells.
These antigens also induce MAIT cell accumulation in mouse lungs after administration with
a co-stimulant. These chemical and immunological ﬁndings provide new insights into antigen
properties and MAIT cell activation.
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T
cells use their surface T-cell receptors (TCRs) to recognize
speciﬁc microbial antigens that are captured and presented
by antigen-presenting cells (APC). T cells are typically
activated by peptides1 or lipids2,3, but mucosal-associated
invariant T cells (MAIT cells)4 are innate-like T cells in the
blood5,6, liver7–12 and gut mucosa9,13,14 that are activated instead
through covalent binding to pyrimidine derivatives that feature a
chemically unstable a-iminocarbonyl Schiff base component
(R1CO–CR2¼NH–)15,16. These antigens are formed from
5-amino-6-D-ribitylaminouracil (1, 5-A-RU), a key intermediate
in the biosynthesis of riboﬂavin (vitamin B2) by many bacteria
and fungi15,17. During microbial riboﬂavin biosynthesis, this
intermediate undergoes enzyme-catalyzed condensation with
3,4-dihydroxy-2-butanone-4-phosphate (2), followed by rapid
cyclization to form 6,7-dimethyl-8-(D-ribityl)lumazine (4a),
which subsequently dismutates to give riboﬂavin (Fig. 1a).
However, 1 can also react through non-enzymatic Schiff base
condensation with a-dicarbonyl compounds (5a-c) (Fig. 1a), such
as glyoxal (5b) and methylglyoxal (pyruvaldehyde, 5c)18,19,
derived from mammalian glycolysis or bacterial metabolism to
give the adducts 5-(1-methyl-2-oxopropylideneamino)-6-D-
ribitylaminouracil (5-MOP-RU, 3a; a riboﬂavin biosynthetic
intermediate), 5-(2-oxoethylideneamino)-6-D-ribitylaminouracil
(5-OE-RU, 3b), and 5-(2-oxopropylideneamino)-6-D-
ribitylaminouracil (5-OP-RU, 3c).
These a-iminocarbonyl adducts 3a-c are very unstable
chemical entities, susceptible to hydrolysis or intramolecular
cyclization to give bicyclic lumazines 4a-c. Nevertheless, 3b and
3c persist long enough to be captured and stabilized through a
covalent bond with Lys43 of the major histocompatibility
complex (MHC) class I-related protein (MR1)15. This creates a
second Schiff base and anchors 3b-c to MR1 for subsequent
presentation to the TCR of MAIT cells (Fig. 1b). The formation of
this covalent bond between the antigen and the antigen-
presenting protein is a striking and novel way to stabilize a
T-cell antigen. Furthermore, although a Schiff base ligand-protein
covalent bond is not without precedence in nature (for example,
pyridoxal phosphate, fructose 1,6-bisphosphate, retinal)20, the
linkage between the uracil and MR1 involves two consecutive
Schiff bases, creating a 1,2-diimino moiety (–NH¼CR1–
CR2¼N–; Fig. 1c) that is unprecedented in biological
chemistry. Crystal structures of the MR1-antigen-TCR ternary
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Figure 1 | Glycolysis metabolites react with a vitamin B2 biosynthetic intermediate to create MAIT cell antigens. (a) Enzymatic biosynthesis of
vitamin B2 (top), and formation of antigens from biosynthetic intermediate 1 by condensation with glycolysis metabolites 5a-c (bottom). (b) Complex of
antigen (blue) sandwiched between MR1 (purple) on the surface of an antigen-presenting cell APC and T-cell receptor protein TCR (orange) on the surface
of a MAIT cell. (c) Interactions observed in a ternary crystal structure of a human MAIT TCR-3c-MR1 complex15, showing antigen (blue)MR1 (purple)
and antigen (green)TCR (orange) contacts, with an extended conjugated system involved in p-interactions (dashed circle).
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complexes reveal that the antigen is almost encircled by MR1,
with multiple hydrogen bonds from the uracil and ribityl
components to MR1 and TCR residues (Fig. 1c)15,21–24. Two
tyrosine residues from MR1 (Y7, Y62) are positioned for
p-interactions with the pyrimidine ring. The novelty and
potential immunological importance of these structures
demands an understanding of the synthesis, structure, and
chemical properties of 3a-c, as well as the identiﬁcation of
stereochemical requirements for antigen potency and stability
and for MR1-dependent MAIT cell activation, all of which are
described here.
Results
Synthesis of unstable MAIT cell antigens. The condensation of
uracil derivative 1 with a-dicarbonyls 5 in water is known25–31 to
produce lumazines (Fig. 1a), but the anticipated putative imine
intermediates 3a-c had not been isolated nor characterized prior
to our work. These ﬂeeting intermediates cannot be efﬁciently
synthesized in water for biological applications for three reasons.
First, the condensation of diamine 1 with unsymmetrical
a-dicarbonyls 5 generates a mixture of inseparable
regioisomers. Second, formation of imines (as in 3a-c) and their
hydrolyses are reversible in water. Third, 3a-c undergo rapid
intramolecular condensation between amine and carbonyl groups
to form bicyclic lumazines 4a-d (Fig. 1a), a process likely to be
driven thermodynamically by aromatization.
These limitations were evident when the reactions between 1
and 5a-c were monitored in water (Fig. 2). For example, the
reaction with 5c was monitored at different pH (pH 7.4, PBS;
pH 5.4, 20mM NH4OAc buffer, 150mM NaCl) and temperature
(37 and 15 C) using analytical LCMS (Supplementary Fig. 1).
Regioisomers can form depending on whether the C-5 amine of 1
condenses with the more reactive aldehyde or the ketone of 5c to
give 4c or 4d, respectively (see Supplementary Figs 22–30 for
NMR spectra). The rate of formation of imines 3c-d and their
subsequent cyclization to lumazines 4c-d were highly dependent
on reaction conditions, with 4c forming preferentially over 4d
with increasing acidity or temperature (Supplementary Fig. 2).
The concentration of 3c typically peaked at approximately
5–10min (Supplementary Fig. 1). Compound 1 reacted even
faster with 5b than 5c, with the concentration of 3b peaking at
1min before completely cyclizing within 30min (pH 7.4, PBS;
15 C) to 4b (Supplementary Fig. 3).
We discovered that the unstable intermediates 3a-c could be
isolated as kinetic products by exploiting key stereochemical
properties, as revealed by the reaction mechanism between 1
and 5 (Fig. 2). Diamine 1 should react with dicarbonyl 5 to
preferentially form hemiaminal 6, as the C-5 amine is more
nucleophilic than the C-6 amine at the b-position of a vinylogous
amide (Supplementary Fig. 2). Elimination of water from 6 gives
trans-3, in which the amine and carbonyl groups are held apart
by the trans-conﬁguration to prevent cyclization, unlike cis-3,
which is preorganized for cyclzation. If the reaction of 1 and 5
was carried out in water, the reaction proceeds under thermo-
dynamic control, with trans-3 rehydrating to 6 followed by bond
rotation and cyclization via 7 (or cis-3) and 8 to give lumazine 4
(Fig. 2). However, the reaction between 1 and 5 in a non-aqueous
solvent should proceed under kinetic control. In this scenario,
trans-3 should form faster than cis-3 from 6 for steric
reasons (Supplementary Fig. 4). Once formed, trans-3 is unlikely
to isomerize to cis-3 as this transformation has a large and
prohibitive activation energy barrier32, estimated by ab initio
gas phase density functional theory (DFT) calculations to be
20–28 kcalmol 1 (Supplementary Fig. 5). Thus, if the formation
of trans-3 from 6 was also faster than the formation of 7, then
trans-3 should accumulate as the kinetic product (Fig. 2).
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Figure 2 | Proposed mechanism for reaction between 1 and 5 to produce uracil and lumazine derivatives. These reactions are reversible in water,
but dehydrative cyclization drives formation of thermodynamically more stable aromatic lumazine derivatives 4. Polar aprotic solvents may facilitate kinetic
control of these equilibria and enable trans-3 to persist in solution.
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The choice of solvent can signiﬁcantly alter the outcome
of a chemical reaction and dictate whether it is kinetically or
thermodynamically controlled33–35. In order to obtain the kinetic
product trans-3, the condensation of 5c with model compound
5-amino-6-methylaminouracil (an analogue of 1) was
investigated by NMR spectroscopy in a polar aprotic solvent
(nitromethane-d3, DMF-d7 or DMSO-d6). However, imine
formation without simultaneous cyclization was only observed
in DMSO-d6 (Fig. 3a), consistent with it having the largest
dielectric constant and an ability to accept hydrogen bond
donors. These properties respectively accelerate the cationic E1
dehydration over the cyclization reaction, and suppress imine
rehydration through solvation of liberated water molecules by
DMSO (Supplementary Fig. 6). The reactions between 1 and 5a-c
in anhydrous DMSO-d6 were studied by 1H and 13C NMR
spectroscopy (Fig. 3). Formation of 3a-c was observed clearly
1
1 + 5c, 1 h
1 + 5c, 16 h
1 + 5c, 40 h
3c, after HPLC
10
100
%
 3
c 50
2
0
0 20 40 4,200
Min
a
3a 3b
3b′
H
N
NH NH
NH
O O
O
O
c′
N
H
H
HO OH
a′
b′
H
N
O O
2J
2J
2J
3J
2J 2J
2J
2J
1J
1J
1J
4J 3J
3J
3J
3J
e
c
c
N
3c
N
H O
O
cb
a
d NH
O
H
N
a a
b bd
O O
e
c
b
2.5
9 8 7 6 5 4 3 2
c
a
a
d
b
c
9.5 9.0 8.510.0
b
a
a’
a
H
N
N
H
H
b b′
c′
c
2.0 1.5
p.p.m.
p.p.m.
100
150
200
p.p.m.
100
50
0
–14 –12 –10 –8 –6
1
3a
3b
3c
 Log [compound] (M)
%
 m
ax
im
al
 a
ct
iva
tio
n
o
f J
ur
ka
t.M
AI
T 
ce
lls
p.p.m.
100
50
150
200
p.p.m.
p.p.m.
100
150
200
dButane-
2,3-dione
Min
0
0
50
100
%
 3
c 
re
m
a
in
in
g
50 100 150 200
In DMSO
DMSO into PBS
In PBS
4,500 4,800
9 8 7 6 5 4 3 2 1 p.p.m.
MeImine CH
C-6 NH Ribityl CH
*
*
*
a
b c
d e
f g
Figure 3 | Formation and solution structures of uracil-based antigens that activate MAIT cells. (a) Exclusive formation of 5-OP-RU 3c from 1 and 5c in
DMSO-d6, as monitored by
1H NMR spectroscopy, with the characteristic signals of 1 and 5-OP-RU 3c as indicated. (b) Formation of 5-OP-RU 3c in DMSO
(black) versus PBS buffer (red). In PBS buffer (red, 2.62mM of 1, 7.86mM of 5c, pH 7.4, 37 C), 3c reached a maximum concentration corresponding to
only 1.1% conversion of 1 at 5min. In DMSO (black, 31.8mM 1 and 34.5mM 5c, room temperature), 5-OP-RU 3c reached 100% conversion after 2 days
and then plateaued. (c) Stability of 5-OP-RU 3c in DMSO (black), PBS buffer (red) and after the DMSO solution was diluted into PBS buffer (blue). Data for
PBS buffer were extracted from b (red) at the time the maximum 5-OP-RU 3c concentration was reached (that is, 5min after mixing). (d–f) HMBC NMR
spectra of 3a-c (DMSO-d6), respectively. Square boxes indicate correlations for the aldehyde form of 3b, and circles for its hydrate form 3b
0. Arrows and
boxes indicate key 1H–13C long-range correlations that unambiguously characterize the compounds. J refers to heteronuclear coupling through 1, 2, 3 or 4
bonds. (g) MAITcell activation. Data represent mean±s.e.m. (n¼ 3). The a-dicarbonyls 5a-c, lumazines 4a-b and the solvent DMSO-d6 were inactive (up
to 15mM), while 4c and 4d had only very weak activity at the highest concentrations tested (EC504100 nM).
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within 1 h (for example, Fig. 3b). The reaction of 1 with the
unsymmetrical 5c gave the regioisomer 3c exclusively, consistent
with the greater reactivity of the formyl than the acetyl group in
5c (Fig. 3a).
Imines 3a-c were much more stable in DMSO than in water
(Fig. 3c and Supplementary Fig. 9), remaining essentially
unchanged (490%) after 2 days in DMSO-d6 at 22 C. Thus,
by using a common aprotic solvent, the outcome of the reaction
was completely diverted to a single kinetic end point without the
use of protecting groups, overcoming the substantial challenge
posed by the instability of 3a-c in water where they convert
rapidly to lumazines 4a-c (ref. 36). After extensive optimization of
conditions, imine 3c could even be puriﬁed by rpHPLC by
minimizing its exposure to water and acid (Fig. 3a and Methods).
However, 3a and 3b were much less stable in aqueous media and
could not be further puriﬁed.
Imines 3a-c were characterized in DMSO-d6 by 1D and 2D
NMR and HRMS (Fig. 3d–f; Supplementary Information). The
imines 3a and 3c were single, stable species in DMSO. The
reaction between 1 and 5b gave an inseparable mixture of imine
3b, its formyl hydrate (gem diol) and the symmetrical bis-imine
adduct (as characterized by the imine singlet at d 9.24 p.p.m.
and ESI-MS m/z¼ 575 [MþH]þ ) in a ratio of 1:1:1.3. Imine 3b
showed characteristic coupling (3JHH¼ 8.0Hz) between the
formyl (9.42 p.p.m.) and imine (8.82 p.p.m.) protons. Meanwhile,
its hydrate showed a doublet (3JHH¼ 6.7Hz) with a chemical shift
(d 5.40 p.p.m.) typical for an acetal proton. All three imines 3a-c
were single geometric isomers, unambiguously characterized
by Heteronuclear Multiple Bond Correlation (HMBC) NMR
spectra, indicating key connectivities within and between the
a-iminocarbonyl unit and the uracil ring (Fig. 3d–f). In 3b and
3c, the imine protons (d 8.81 and 8.70 p.p.m., respectively)
showed 3JHC correlations to the ring C-5, with the methyl signal
at d 1.82 p.p.m. making the analogous 4JHC correlation for imine
3a. The imine protons of 3b and 3c also showed 2JCH correlations
to carbonyl carbons (d 194.5 and 200.2 p.p.m., respectively), while
the methyl proton signal at d 1.85 p.p.m. of 3a showed a 3JHC
correlation with a carbonyl carbon at d 199.7 p.p.m., proving that
cyclization of 3a-c had not occurred.
The chemical stabilities of 3a-c were determined in various
aqueous buffers (Supplementary Fig. 7). In PBS buffer (pH 8.0,
15 C), the half-life of 3a could not be measured as it had
completely degraded in o5min, while 3b decayed exponentially
with a half-life of 18min. The homologue 3c was more stable with
a half-life of 14 h, consistent with a slower attack on the more
hindered carbonyl of 6c than 6b. The half-life of 3c decreased
substantially with increasing acidity and temperature. At 15 C
and 0.065mM, its half-life decreased to 12 h at pH 6.8 (MilliQ
water) to 44min at pH 5.4. It decayed linearly with time at pH 6.8
and pH 8.0, but exponentially at pH 5.4. Under physiological
conditions (PBS, pH 7.4, 37 C), its half-life was 88min. In
aqueous media, 3c degraded to give exclusively lumazine 4c
without forming isomer 4d at pH 6.8–8.0.
Next, we evaluated how the 5-OP-RU 3c formation and
degradation kinetics impacted on its preparation and potential
use as an immunological reagent. In our previous studies,
5-OP-RU 3c was prepared by mixing 5-A-RU 1 with methyl-
glyoxal 5c in aqueous media and then used in immunological
studies in vitro. However, when 5-A-RU 1 and methylglyoxal
5c are mixed in PBS buffer (pH 7.4 and 37 C),
5-OP-RU 3c reaches a maximum conversion of only 1.1%, before
very rapidly degrading with a half-life of 12min, indicating that
the purity of the desired compound generated in the mixture
was extremely low (Fig. 3b). In contrast, when 5-A-RU 1 and
methylglyoxal 5c were combined under argon in DMSO-d6,
5-OP-RU 3c was formed as the sole product and still intact after
72 h (Fig. 3a,b). Prepared in this way, 5-OP-RU 3c was stable in
DMSO solution (495%) for days at room temperature. When
this DMSO solution of 5-OP-RU 3c was diluted into aqueous
buffer (PBS, pH 7.4, 37 C) its half-life also increased more
than sevenfold (half-life¼ 88min) (Fig. 3c). Thus, pre-forming
5-OP-RU 3c in DMSO-d6 as a kinetic product and then diluting
into aqueous buffer yielded a product of substantially higher
purity, in greater quantity and with much higher stability than in
our previously reported aqueous preparations.
Comparison of MAIT cell activation by 3a-c. MAIT activation
was evaluated using a well established reporter assay17 by
co-culturing two cell lines (human MAIT TCR-transduced
Jurkat T cells and MR1-overexpressed C1R cells, Fig. 3g).
Imine 3c (effector concentration for half-maximum response
(EC50) 1.6 pM) was the most potent antigen. Although the
high-resolution ternary MR1-antigen-TCR crystal structures of
3b-c were nearly identical15, 3b (EC50 510 pM) was 2 orders of
magnitude less potent than 3c, consistent with its reduced
chemical stability in water. Imine 3a might also be expected to act
as an antigen for the MAIT cell mediated detection of microbial
infections due to its structural homology to 3b-c and its role
as a putative intermediate in bacterial riboﬂavin biosynthesis.
However, consistent with the inability of mixtures of 1 and 5a to
refold MR1 (ref. 15), imine 3a (EC50 24 nM) was found to be
signiﬁcantly less active than 3b-c (Fig. 3g), a result attributable to
its extreme instability in water.
Conformational analysis of 3a-c. To better understand the
relative potencies and stabilities of 3a-c, which have almost
identical chemical structures, ab initio DFT calculations
(at the level of B3LYP/6-311þ g(d,p)) were used to predict their
optimized structures (Fig. 4a). Compounds 3b-c showed
little deviation from conformations that we observed in crystal
structures, with the C-6 nitrogens, uracil rings and iminocarbonyl
moieties notably coplanar. This implied that the solution
conformations of 3b-c were likely to be close to their optimal
MR1-binding conformation, consistent with MR1 requiring 3b-c
in order to fold into a biologically functional ternary structure,
a process that caused little conformational perturbation to the
antigens, according to these calculations.
Unexpectedly, 3a had a signiﬁcantly different modelled
conformation to 3b-c despite their structural similarity. Due to
a steric clash between the imine methyl and the C-4 uracil
carbonyl, the iminocarbonyl and the ribityl moieties were twisted
out of the uracil ring conjugation plane by  43.0 (c) and
 5.3 (f), respectively. Further, as the imine was twisted out of
the plane of ring conjugation, the imine hydration of 3a (to give
6a, Fig. 2a) would not disrupt conjugation and was likely to
incur a lower energetic penalty than 3b-c, leading to increased
susceptibility to cyclization and imine hydrolysis. The
signiﬁcantly different electronic structures (based on LUMOs)
of 3a and 3b-c were consistent with a loss of conjugation in 3a
(Supplementary Fig. 8). Together, the inability to adopt the ﬂat
conformation needed for binding and the increased imine
hydration susceptibility rationalizes the greatly reduced antigenic
activity of 3a relative to 3b-c and represents a crucial distinction
between the productive riboﬂavin biosynthetic intermediate 3a
and off-pathway by-products of the much more potent antigens
3b and 3c. The apparent MAIT activity of 3a should therefore be
cautiously interpreted, but may be attributable to facile hydrolysis
to 1. Under the cell assay conditions, compound 1 can
subsequently react with endogenous 5b-c to give trace 3b-c.
Moreover, the potency of 1, which can neither refold nor form a
Schiff base with MR1, was dependent on the concentration of
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dicarbonyl 5b-c, suggesting that its apparent EC50 18 nM was also
due to its ability to reform trace amounts of 3b-c.
Design and synthesis of a stable T-cell antigen. Having
synthesized the unstable but potent antigens 3b-c, we sought to
create a potent antigen that was chemically stable. As the energy-
minimized conformations of 3b-c were similar to those found in
their ternary TCR-antigen-MR1 crystal structures15 (Fig. 4a),
we hypothesized that MAIT cell activation may be related to
conformational similarity of an antigen to 3c in the crystal
structure. Thus, analogue 9 was designed from 3c, in which the
nucleophilic C-6 amine was N-methylated in order to retard
cyclization (Fig. 4b). Then, 10 was designed from 9 by replacing
the hydrolytically susceptible imine with an oleﬁn (Fig. 4b).
These changes were not expected to affect MR1 binding
directly as neither the C-6 nor C-5 nitrogens of 3c made direct
contact with the MR1 protein in the crystal structure15 (Fig. 1c).
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C5-C4, respectively. In order to visualize the twisting of these substituents, the LUMOs (with orbital phases in cyan and blue) are shown for clarity.
The incorporation of a methyl group to 3c (that is, 3a, 9 or 10) resulted in a twisting of the C-5 substituent relative to the ring and an inversion of the LUMO
phase at the carbonyl carbon (3a and 10). These changes likely impact the ability of the ligands to form non-covalent interactions with MR1 and MAIT TCR
(Fig. 1), as well as their reactivity towards the formation of Schiff base with K43 of MR1. (c,d) Plots illustrating the structural similarity of the compounds
based on the dihedral angles f (red) and c (blue), and the distances d1 (purple) and d2 (green).
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The conformational agreement of 9 and 10 to 3c was assessed by
calculating their energy minimized structures. The iminocarbonyl
and the ribityl moieties of 9 were twisted slightly (f¼ 8.6 and
c¼ 4.0) due to the additional steric bulk at the C-6 amine
(Fig. 4b, c). Consistent with this, the distances between the
carbonyl carbon and the C-6 amine or the 20-hydroxyl (d1 and d2,
respectively) were slightly elongated compared to 3c (Fig. 4b, d).
The oleﬁn and ribityl moieties of 10 were signiﬁcantly more
twisted (f¼  16.8 and c¼  16.3) with d1 and d2 further
elongated. Thus, replacing the N-methylamine of 10 with the
smaller methylene group gave a third analogue (11) (Fig. 4b),
which was expected to have even greater stability due to the
removal of a nucleophile. The energy minimized 11 showed
greater conformational similarity to 3c, with the enone, uracil
ring and the C-6 carbon essentially coplanar (Fig. 4b, c).
However, the ribityl chain was more distorted, possibly due to
a change in hybridization (N-sp2 to C-sp3) causing a bond angle
decrease (b¼ 123.6 to 112.8) at the ribityl-uracil linkage site.
To assess their antigenic potencies and stabilities, 9–11 were
synthesized (Fig. 5). Compound 9 was synthesized via the
addition of N-methylribitylamine 12 to chloronitrouracil 13
to give 14, followed by nitro reduction (to give 15) then
condensation with methylglyoxal (Fig. 5a). Compound 10 was
synthesized by ﬁrst introducing the enone substituent via a Wittig
oleﬁnation on 16 (prepared via an ortho-lithiation/formylation
sequence), followed by an aza-Michael-type chloride displace-
ment by N-methylribitylamine 12 at the doubly activated C-6
position (Fig. 5b). The synthesis of 11 (Fig. 5c) was challenging,
as there was almost no precedence for the synthesis of
delicately functionalized 5,6-dialkyl uracils. Our initial approach
of C-6 functionalization by directed ortho-lithiation37,38
was unsuccessful, presumably due to chelation effects from
the substrate’s polyoxygenated ribityl chain. Subsequently,
we envisaged a construction of the uracil ring from the
corresponding ribityl b-ketoester 25, a key retrosynthetic
decision that allowed ribose-derived aldehyde 20 (ref. 39) to be
elaborated with a stabilized ylide 21 without a-epimerization. In
the forward synthesis, aldehyde 20 was alkylated with ylide 17
under neutral conditions to give 22 (83%). Contrary to the
reported reactivity of ylide 21 under neutral40,41 or basic42
conditions, we found that 20 reacted with 21 to give only trace
amounts of 24 or led to signiﬁcant a-epimerization under various
conditions. Hydrogenation of 22 gave 23 quantitatively and then
a-carboxylation with Mander’s reagent43 gave b-ketoester
25 (70%). Condensation with thiourea gave thiouracil
26 (quant.)44, which was desulfurized unconventionally45 under
basic conditions with 1-butene oxide to yield 27 (84%),
preserving the acetonide protecting groups. After investigating
reaction conditions on the model compound 6-methyluracil, the
methyl vinyl ketone moiety of 29 was installed in one step with
alkyne 28 (35%). Finally, deprotection of 29 with 1M HCl
in THF gave 11 (78%). The structures of 9, 10 and 11 and
their synthetic precursors were unambiguously conﬁrmed by
HRMS and NMR (Supplementary Methods and Supplementary
Figs 31–58).
Stability and MAIT cell activation of synthetic analogues. The
chemical stability and antigenic activities of these analogues were
assessed. Despite the additional bulk at the nucleophilic C-6
nitrogen, 9 was less stable than 3c (Fig. 6a), cyclizing readily to
the corresponding quaternary ammonium species. However, as in
3a, the reduced stability of 9 was consistent with twisting of the
iminocarbonyl moiety out of the conjugation plane (f¼ 8.6 and
c¼ 4.0), likely leading to an increased susceptibility to imine
hydration. Although the iminocarbonyl group of enone 10 was
even more twisted, it was more stable than 9 as the alkene was
more resistant to hydration. Nonetheless, it still degraded to give
the corresponding cyclic quaternary ammonium species. Finally,
11 was completely water stable with no degradation observed
over 5 days (PBS buffer, pH¼ 7.4, 37 C).
The antigenic activity of 9 (EC50¼ 14±14 nM) was reduced by
four orders of magnitude compared to its parent imine 3c, while
the more stable enone analogues 10 and 11 exhibited disparate
potencies of 410 mM and 1.6 nM, respectively (Fig. 6b). These
relative potencies were consistent with the hypothesis that a
better conformational match to 3c, especially with respect to the
dihedral angle c, would result in greater antigenic potency
(Fig. 4c). To support this idea further, the overall conformational
distortion of the ligands was quantitatively evaluated, reasoning
that the energies expended by 9–11 to adopt the ideal bioactive
conformation would be related to their antigenic activities. Thus,
9–11 were modelled by making the necessary atom connectivity
changes to the 3c conformer bound in the MR1-3c-TCR crystal
structure. The energies of these ‘bioactive’ conformers and
the energy-minimized conformers were then calculated using
Gaussian. Their differences inversely correlated with their activity
(pEC50), supporting the conformational matching hypothesis
(Fig. 6c). Together, 9–11 provide an important base for the
delineation of further structure-activity relationships to optimize
these antigens and to clarify the molecular determinants of MR1
binding versus MAIT cell activation.
Functional proﬁling of analogue 11. To demonstrate the utility
of analogue 11 in MAIT cell-related immunological studies,
we performed in vitro and in vivo functional assays. We have
previously shown upregulation of MR1 surface expression for 3c
and also for the MAIT-non-stimulatory MR1 ligand acetyl-6-
formylpterin (Ac-6-FP, 30)21,46. Here we incubated C1R.MR1
cells with a range of concentrations of 3c, 9–11 or 30 over a 24 h
time course and detected MR1 expression by staining with the
monoclonal antibody 26.5 (3c, 11 and 30 shown in Fig. 7a;
all compounds and dose titration of 3c and 11 shown
in Supplementary Fig. 9). Compounds 3c and 11 showed
comparable early upregulation of MR1, but the upregulation
caused by 3c peaked at 4 h then reduced, consistent with turnover
of MR1 in the cells46 and instability of 3c in aqueous solution. In
contrast, MR1 surface expression continued to increase over 24 h
in the presence of 11 to a similar level as induced by 30 (ref. 46),
consistent with 11 being chemically more stable in water than 3c.
Next, we examined whether 11 was capable of refolding MR1
for the generation of tetramer reagents. Indeed, human MR1
was readily refolded in the presence of 11 (not shown) and
tetramers were generated in parallel to 3c (that is, MR1-5-OP-RU
tetramers15,23). When used to detect cells within human peri-
pheral blood mononuclear cells (PBMCs) from four healthy
blood donors, 494% of TCR TRAV1-2þCD161hiCD3þ cells
(MAIT cells) co-stained with both tetramers, but no distinct
staining was observed for conventional T cells expressing
TRAV1-2 (Fig. 7b).
To assess the ability of 11 to activate MAIT cells, human
PBMCs were cultured alone, or with THP-1 cells, in the presence
of the compounds, and cytokine production assessed by
intracellular cytokine staining. Similar to 3c, 11 stimulated the
production of interferon-g (IFNg) and tumour necrosis factor
(TNF) by human MAIT cells (Fig. 7c), indicating that it is
functionally comparable to 3c.
Finally, we utilized our established mouse model47 to examine
the MAIT cell response to analogue 11 in vivo. In this model, we
previously showed that accumulation of MAIT cells occurs in the
lungs after intranasal administration of 3c and a co-stimulant,
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such as Toll-like receptor (TLR) agonists. Thus, we used TLR
agonist CpG oligodeoxynucleotides with either 3c or 11 at a range
of doses. Both compounds were capable of causing MAIT cell
accumulation in the lungs (Fig. 7d), albeit with different
efﬁciencies. Thus, 11 has the same functional proﬁle as 3c in
both in vitro and in vivo assays examined to date.
Discussion
MAIT cells are an abundant population of innate-like T cells
recognized relatively recently and considered to be involved in
many immunological and pathological processes9,48–50. The
identity of the natural antigens was elusive until recently, when
we discovered that they were uracil-based imines 3, formed by a
Schiff base condensation between bacterial riboﬂavin biosynthetic
intermediate 1 and the a-dicarbonyl glycolysis metabolites 5
(ref. 15). Unfortunately, antigens 3 are very unstable in water,
necessitating the development of a practical synthesis in order to
more effectively investigate their immunology and pharmacology.
We found that although compounds 3a-c form only transiently
and in small quantities during the reaction between 1 and 5 in
water, they were formed exclusively in high yield as long-lived
kinetically stable products in DMSO. Importantly, when 3 was
isolated from DMSO, it degraded to 4 much more slowly in water
than from mixtures of 1 and 5 in water under the same
conditions, suggesting a mechanism involving direct conversion
of 6 to 4 with very little formation of the immunologically active 3
in water. Taken together, the superior preparation of 5-OP-RU
3c in DMSO under kinetic control can dramatically improve its
utility as an immunological reagent compared to our previously
reported aqueous-based preparation (Fig. 3b, c). In addition,
this study rationalizes mechanistically and demonstrates
experimentally the different aqueous stabilities and potencies
(EC50 510 and 1.6 pM, 3b and 3c respectively) of these unstable
a-iminocarbonyl compounds as MAIT cell antigens. Compounds
9–11 were synthesized as analogues of 3c in attempts to improve
antigen stability, with 11 shown to be the most potent analogue
that was completely stable in water. Despite the chemical and
structural similarities of 3c and 11, their different potencies
suggest a very speciﬁc conformational requirement for antigen
recognition of the MR1-TCR complex. Nevertheless, since 11
shows a similar functional proﬁle to 3c in vitro and in vivo,
is indeﬁnitely stable in water and easier to handle, it is a
potentially useful new reagent for the study of MAIT cells.
Furthermore, this study has provided conformational insights for
rational design of new MAIT cell antigens and lays the
foundation for a better understanding of MAIT cell recognition
and activation in immunological responses.
Methods
General experimental methods for NMR, HPLC and LCMS for monitoring kinetics
of formation and stability in aqueous media, and MAIT cell activation assay were
conducted as described previously15,17.
Materials. Glyoxal, methylglyoxal (both as 40% solutions in water), and
butane-2,3-dione (neat) were purchased from Sigma-Aldrich. 5-Amino-6-D-
ribitylaminouracil degrades oxidatively in air31,51, so it was freshly generated under
argon in the dark by reduction with sodium dithionite (3 eq) of the corresponding
5-nitroso-6-D-ribitylaminouracil precursor, prepared following a literature
procedure26 with modiﬁcations (Supplementary Information). Methylglyoxal
(40% solution in water) degrades with prolonged storage; to minimize this,
new commercial samples were aliquoted and stored at  80 C.
Synthesis and characterization of a-carbonyl imines 3a-c. A solution of freshly
prepared amine 1 was adjusted to pH 7.0 using 1M NaOH and lyophilized. The
powdered 1 (70mg, containing sodium sulfate from its preparation) was suspended
in DMSO-d6 (1 g) under argon, and then mixed at rt for 1min. The mixture
was ﬁltered through a HPLC syringe ﬁlter to remove salts, degassed in vacuo,
purged with argon, and transferred to an NMR tube preﬁlled with argon. The
concentration was determined by PULCON NMR spectroscopy (typically 50mM,
NMR spectra in Supplementary Data 1)52. Glyoxal (2.0 equivalents), methylglyoxal
(1.1 equivalent) or butane-2,3-dione (2.0 equivalents) was added, and the reaction
monitored by 1H NMR. Within 1 h, the reaction was observed clearly and the
various unstable a-carbonyl imines 3a and 3b were characterized by 1D and
2D NMR (Supplementary Figs 15–21). In the case of compound 3c, the reaction
was allowed to stand at room temperature for 48–72 h to reach completion.
The solvent was removed in vacuo at room temperature (4 h) with magnetic
stirring. The residue was dissolved in 5ml of 20mM pH 5.4 aqueous NH4OAc
and then immediately puriﬁed using a Shimadzu preparative HPLC system
equipped with a Phenomenex Luna 10 micron C18 250 21.2mm column
(P/No 00G-4253-PO-AX) and a SPD-M20A diode array detector (monitored at
wavelength l365 nm). Flow rate was 20mlmin 1 with linear gradient: 100%
solvent A to 100% solvent B over 30min where solvent A was 20mM ammonium
acetate pH 5.4 in H2O and solvent B was 20mM ammonium acetate pH 5.4 in
MeCN-H2O (80:20, v/v). Immediately after the collection of the product peak
(9.1min), the pH of the fraction was adjusted accurately to 8.3 with 0.05% w/w
ammonia aqueous solution. The solution was frozen immediately (dry ice/acetone
bath) and lyophilized in an acid-free environment. The resultant light
purple material was redissolved in milliQ water, then immediately frozen and
re-lyophilized. The product was obtained as a yellow powder (31% yield; NMR
spectra in Supplementary Figs 20–21).
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with PMAþ ionomycin. One representative mouse (from 4) per group is shown. Experiments were performed twice. See Supplementary Fig. 12 for gating
strategy.
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5-(1-Methyl-2-oxopropylideneamino)-6-(1-D-ribitylamino)uracil (3a).
1H NMR (600MHz, DMSO-d6, key signals only): d 1.83 (s, 3H, N¼CMe),
2.40 (s, 3H, MeCO); 13C NMR (150MHz, DMSO-d6): d 17.2 (N¼CMe),
24.9 (MeCO), 159.8 (N¼C), 199.7 (C¼O); HRMS (m/z): [M] calcd. for
C13H19N4O7, 343.1259; found, 343.1250.
5-(2-Oxoethylideneamino)-6-(1-D-ribitylaminouracil (3b): 1H NMR (600MHz,
DMSO-d6, key signals only): d 8.83 (d, J¼ 8.0Hz, 1H, N¼CH), 9.41
(d, J¼ 8.1Hz, 1H, CHO); 13C NMR (150MHz, DMSO-d6): d 142.0 (N¼C), 194.5
(CH¼O); HRMS (m/z): [M] calcd. for C11H15N4O7, 315.0946; found, 315.0944.
5-(2-Oxopropylideneamino)-6-(1-D-ribitylamino)uracil 3c: 1H NMR
(600MHz, DMSO-d6): d 2.28 (s, 3H, Me), 3.39–3.43 (m, 2H), 3.47–3.51 (m, 1H),
3.52–3.56 (m, 1H), 3.56–3.61 (m, 2H), 3.73 (m, 1H), 7.43 (br s, 1H), 8.80 (s, 1H,
N¼CH); 13C NMR (150MHz, DMSO-d6): d 23.5 (Me), 44.1, 63.1, 70.7, 72,8, 72.9,
98.5 (C¼N–C), 142.0 (br, N¼C), 152.1 (br), 157.6 (br), 159.1, 200.2 (C¼O);
HRMS (m/z): [M] calcd. for C12H17N4O7, 329.1103; found, 329.1116.
Chemical characterization data of compound 11. 1H NMR (600MHz, 10%
D2O/H2O): d 1.75–1.81 (m, 1H), 1.92–1.98 (m, 1H), 2.35 (s, 3H), 2.79–2.91
(m, 2H), 3.57–3.61 (m, 2H), 3.66–3.69 (m, 1H), 3.74–3.77 (m, 2H), 7.21
(d, J¼ 16.0Hz, 1H), 7.52 (d, J¼ 16.0Hz, 1H); 13C NMR (150MHz, 10%
D2O/H2O): d 27.0, 27.2, 30.1, 62.9, 70.7, 72.4, 74.3, 105.9, 127.8, 136.4, 151.9,
161.3, 165.0, 205.2; HRMS (m/z): [M]þ calcd. for C14H21N2O7, 329.1343; found,
329.1348.
Stability of compounds 3a-c and 9–11 in aqueous media. Stock solutions of
either crude (3a, 3b and 9) or puriﬁed compounds (3c, 10 and 11) in DMSO-d6,
with a known concentration calibrated using the PULCON NMR technique52, were
dissolved in aqueous buffers, such as TBS buffer (10mM Tris, 150mM NaCl, pH
8.0), PBS (pH 7.4), MilliQ water (pH 6.8), or aqueous ammonium acetate buffer
(20mM, pH 5.4, 150mM NaCl). Consumption of 3 was monitored by LCMS. The
degradation curves and half-lives under various conditions were summarized in
Fig. 6a and in Supplementary Fig. 7.
MAIT reporter cell activation assay. MAIT reporter cell activation assays and
MR1 upregulation assays were performed by slight modiﬁcations to reported
methods17. Brieﬂy, Jurkat cells transduced with genes encoding a MAIT TCR
comprising the TRAV1-2-TRAJ33 invariant a chain, and a TRBV6-1 b chain,
were tested for activation by co-incubation with compounds and C1R antigen-
presenting cells expressing MR1 (CIR.MR1) for 16 h or over a time course as
indicated. Cells were subsequently stained with PE-Cy7-conjugated anti-CD3
(UCHT1, eBioscience, 1:300), and APC-conjugated anti-CD69 (BD, 1:25)
antibodies as well as biotinylated anti-MR1 mAb 26.5, a gift from Dr Ted Hansen,
Washington University School of Medicine, St Louis, MO53, followed by
Streptavidin-PE (BD, 1:1,000), before analysis by on a FACS CantoII (BD) ﬂow
cytometer. Activation of Jurkat.MAIT was measured by an increase in surface
CD69 expression. MR1 expression was detected on gated C1R.MR1 cells in the
same assay.
Generation of MR1–11 and MR1-5-OP-RU tetramers. MR1 refolding was
performed by slight modiﬁcations to reported methods17. Human MR1-5-OP-RU
3c, human MR1–11 tetramers, and mouse MR1-5-OP-RU tetramers were prepared
by known methods15. Genes encoding soluble human MR1 or human b2m were
expressed for 4 h in BL21 E. coli following induction with 1mM isopropyl
b-D-1-thiogalactopyranoside. E. coli were pelleted and resuspended in a buffer
containing 50mM Tris, 25% (w/v) sucrose, 1mM EDTA, 10mM DTT pH 8.0.
Inclusion body protein was then extracted by lysis of bacteria in a buffer containing
50mM Tris pH 8.0, 1% (w/v) Triton X-100, 1% (w/v) sodium deoxycholate,
100mM NaCl, 10mM DTT, 5mM MgCl2 and 1mg DNaseI per litre of starting
culture; and subsequent steps involved homogenization with a polytron
homogenizer, centrifugation, and washing inclusion body protein sequentially with
ﬁrstly a buffer containing 50mM Tris pH 8.0, 0.5% Triton X-100, 100mM NaCl,
1mM EDTA, 1mM DTT, and secondly a buffer containing 50mM Tris pH 8.0,
1mM EDTA, 1mM DTT. Inclusion body protein was then resuspended in a buffer
containing 20mM Tris pH 8.0, 8M urea, 0.5mM EDTA, 1mM DTT and following
centrifugation the supernatant containing solubilized, denatured inclusion body
protein was collected and stored at  80 C.
C-terminal cysteine-tagged MR1 and b2m were refolded with ligand essentially
as described15. Brieﬂy, in order to generate MR1-5-OP-RU and MR1–11, 28mg of
MR1 and 14mg of b2m inclusion body proteins were refolded with 5-A-RU
(5.25 mmol) and methylglyoxal (1.77mmol), or compound 11 (1.92 mmol),
respectively. Refolded MR1-Ag was then puriﬁed by sequential DEAE
(GE Healthcare) anion exchange, S75 16/60 (GE Healthcare) gel ﬁltration,
and MonoQ (GE Healthcare) anion exchange chromatography. Cysteine-tagged-
MR1-5-OP-RU or MR1–11 were then reduced with 5mM DTT for 20min prior to
buffer exchange into PBS using a PD-10 column (GE Healthcare), and biotinylated
with Maleimide-PEG2 biotin (Thermoscientiﬁc) with a 30:1 molar ratio of
biotin:protein at 4 C for 16 h in the dark. Biotinylated MR1 was subjected to S200
10/300 GL (GE Healthcare) chromatography to remove excess biotin. Biotinylated,
MR1-5-OP-RU or MR1–11 monomers were tetramerized with streptavidin
conjugated to either PE (SA-PE) or Brilliant Violet 421 (SA-BV) (BD Pharmingen).
Tetramer staining of human PBMCs. Healthy donor blood packs were obtained
through the Australian Red Cross Blood Service after approval from the Melbourne
University Human Research Ethics Committee and PBMCs were prepared by
separation on Ficoll–Paque Premium (GE Healthcare). Cells were then washed
twice prior to resuspension in 10% DMSO in FCS. Prior to use, PBMCs were stored
in liquid nitrogen. Approximately 2 106 cells were stained with human MR1-5-
OP-RU tetramer (BV421), human MR1–11 tetramer (PE) and monoclonal anti-
bodies to CD3 (AlexaFluor700, OKT3, eBioscience, 1:50), CD161 (PE-Cy7, HP-
3G10, Biolegend, 1:50) and TRAV1–2 (APC, clone 3C10, Biolegend, 1:50) for
30min on ice and ﬁxed in 1% paraformaldehyde before acquisition of data on a BD
LSR-Fortessa. Data were analyzed using FlowJo software (Tree Star).
In vitro PBMC stimulation assay. Stimulation of PBMCs was performed
essentially as previously described17. Brieﬂy, 5 105 PBMCs were cultured, alone
or with 1 105 THP-1 cells, overnight with or without compounds 3c or 11 at a
range of doses or with PMA and ionomycin (5 ngml 1 and 1 mgml 1 ﬁnal
concentrations, respectively) as a positive control. BD GolgiStop (1:1,000 dilution)
was added after the ﬁrst hour of stimulation. Cells were stained for surface markers
using human MR1-5-OP-RU tetramer (PE, 1:300), and monoclonal antibodies to
CD3 (PE-CF594, UCHT1, BD Horizon, 1:50), CD161 (PE-Cy7, HP-3G10,
Biolegend, 1:50) for 30min on ice and ﬁxed in 1% paraformaldehyde before
cytokine production by MAIT cells was detected by intracellular cytokine staining
with monoclonal antibodies to TNF (APC, MAb11, eBioscience, 1:50) and IFNg
(AlexaFluor700, B27, BD 1:50) in the presence of 0.3% saponin. Data was acquired
on a BD LSR-Fortessa and analysed using FlowJo software (Tree Star).
In vivo assay. Mice were bred and housed at the Biological Research Facility of the
Peter Doherty Institute (Melbourne, Victoria, Australia). Male adult (6–10 weeks)
C57BL/6 mice were used for all experiments, after approval by the University of
Melbourne Animal Ethics Committee. CpG 1688 sequence: 50-T*C*C*A*T*G*A*
C*G*T*T*C*C*T*G*A*T*G*C*T-30 (*phosphorothioate linkage) nonmethylated
cytosine-guanosine oligonucleotides was purchased from Geneworks (Australia).
Mice were inoculated with 20 mg CpG once per nares, plus 3c or 11 at indicated
doses and MAIT cells were detected from lungs at day 7 as previously described47.
Cytokine production by isolated MAIT cells was detected by intracellular cytokine
staining47. Brieﬂy, mice were sacriﬁced by administration of CO2 and lungs taken
following heart perfusion with 10ml cold RPMI. To prepare single cell suspensions,
lungs were ﬁnely chopped with a scalpel blade and treated with 3mgml 1
collagenase III (Worthington), 5 mgml 1 DNAse and 2% FCS in RPMI for 90min
at 37 C with gentle shaking. Cells were then ﬁltered (70mM) and washed with
PBS/2% FCS. RBCs were lysed with hypotonic buffer TAC (Tris-based Amino
Chloride) for 5min at 37 C. Approximately 1.5 106 cells were ﬁltered (40mm)
and used for ﬂow cytometric analysis.
Ab against CD19 (1D3, PerCP-Cy 5.5, 1:200), CD45.2 (104, FITC, 1:200), IFNg
(XMG1.2, PE-Cy7, 1:400), TCRb (H57–597, APC or FITC, 1:200) and IL-17A
(TC11-18H10, PE, 1:200) were purchased from BD. To block non-speciﬁc staining,
cells were incubated with MR1-6FP tetramer and anti-Fc receptor (2.4G2)
for 15min at room temperature, then incubated at room temperature with
antibody/tetramer cocktails in PBS/2% FCS. 7-AAD (5 ml per sample) was added
for the last 10min. Cells were ﬁxed with 1% PFA prior to analysis on LSR Fortessa
(BD Bioscience) ﬂow cytometer. Data analysis was performed with FlowJo
software. For intracellular cytokine staining (ICS), Golgi plug (BD Biosciences)
was used during all processing steps. Cells stimulated with PMA/Ionomycin
(20 ngml 1, 1 mgml 1 respectively) for 3 h at 37 C were included as positive
controls. FVD (eBioscience) were added for 30min at 4 C before surface staining.
Surface staining was performed at 37 C and cells stained for intracellular cytokines
using the BD Fixation/Permeabilisation kit or transcription factors using the
transcription buffer staining set (eBioscience) according to the manufacturers’
instructions.
Data availability. The authors declare that the data supporting the ﬁndings of this
study are available within the paper and its Supplementary Information ﬁles. FIDs
of the NMR spectra are available from the authors upon request.
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